PHase II trial of anti-IL-6 receptor antibody (MRA) for systemic-onset juvenile idiopathic arthritis. Yokota S,Imagawa T,Mori M, et al. Autoimmunity Reviews . 2004Yokota S, Imagawa T, Mori M, Miyamae T, Nishimoto N, Kishimoto T. Phase II trial of anti-IL-6 receptor antibody (MRA) ...
Anti-IL-6 receptor antibody, MRA (tocilizumab: anti-human IL-6 receptor antibody) and MR 16-1 (anti-mouse IL-6 receptor antibody) were kindly provided by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Human recombinant IL-6 was purchased from BD Pharmingen (Franklin Lakes, NJ, USA). ...
After 2 years of MRA treatment, the disease activity was well controlled without adverse reactions. Anti-IL-6R MoAb can be a novel and effective therapeutic agent for AIHA. 展开 关键词: AIHA IL-6 Humanized anti-IL-6 receptor antibody
OBJECTIVE: To investigate the safety and efficacy of MRA, a recombinant human anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody of the IgG1 subclass that inhibits the function of IL-6, in patients with established rheumatoid arthritis (RA). METHODS: A randomized, double-blind, placebo...
An anti-IL-6 receptor monoclonal antibody, such as MRA, may have an important role to play, not only in relieving the patient of the systemic ... P Woo,N Wilkinson,AM Prieur… - 《Arthritis Research & Therapy》 被引量: 558发表: 2005年 A national registry for juvenile dermatomyositis and...
Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Tocilizumab (namely MRA), a humanized anti-interleukin (IL)-6 receptor monoclonal antibody, is under development by Roche for the treatment of inflammatory... Changhai Ding, Graeme Jones - 《Reviews on Recent Clinical...
et al. An anti-TNF-α antibody mimetic to treat ocular inflammation. Sci. Rep. 6, 36905; doi: 10.1038/srep36905 (2016). Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This work is licensed under a ...
Objective To establish the safety and efficacy of repeat infusions of tocilizumab (previously known as MRA), a humanized anti-interleukin-6 (IL-6) receptor... RN Maini,PC Taylor,J Szechinski,... - 《Arthritis & Rheumatology》 被引量: 1260发表: 2010年 ...
L Iannone2, R Carotenuto1, S Biffo3,4, A Vitale5 and C Campanella*,1 p27BBP/eIF6 (b4-binding protein/eukaryotic initiation factor 6) regulates the joining of 40S and 60S ribosomal subunits, on receptor for activated C kinase 1 binding and protein kinase C phosphorylation in serine 235...
variations occur in the extracellular domain of MUC1 and have no influence on the cytoplasmic domain, which is recognized by the primary antibody. In summary, the results shown in Fig. 1 confirm the existing knowledge that ZR-75-1 strongly overexpresses mucin 1, while the other three cell...